Compare ARVN & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | TRTX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 606.5M |
| IPO Year | 2018 | N/A |
| Metric | ARVN | TRTX |
|---|---|---|
| Price | $10.04 | $8.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 4 |
| Target Price | ★ $15.05 | $9.83 |
| AVG Volume (30 Days) | ★ 640.4K | 525.6K |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 11.55% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | $8.78 |
| Revenue Next Year | N/A | $4.14 |
| P/E Ratio | ★ N/A | $14.82 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.90 | $7.44 |
| 52 Week High | $14.22 | $9.85 |
| Indicator | ARVN | TRTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 56.72 |
| Support Level | $9.96 | $8.45 |
| Resistance Level | $10.18 | $8.72 |
| Average True Range (ATR) | 0.55 | 0.19 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 20.36 | 43.64 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.